Antibody-X Conjugates
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
83
NCT06809114
FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: Nov 1, 2025
Completion: Aug 31, 2028
Loading map...